Stockscreener 앱 받기
0.9702
4.88%
-0.0498
시간 외 거래:
.96
-0.0102
-1.05%
전일 마감가:
$1.02
열려 있는:
$1.03
하루 거래량:
89,558
Relative Volume:
0.17
시가총액:
$7.84M
수익:
$2.35M
순이익/손실:
$-2.56M
주가수익비율:
-2.1651
EPS:
-0.4481
순현금흐름:
-
1주 성능:
-34.00%
1개월 성능:
-38.59%
6개월 성능:
-43.92%
1년 성능:
-54.35%
1일 변동 폭
$0.9701
$1.03
1주일 범위
$0.9701
$1.53
52주 변동 폭
$0.9701
$2.483
이뮤론 Stock (IMRN) Company Profile
IMRN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMRN
Immuron Limited Adr
|
0.9702 | 8.24M | 2.35M | -2.56M | 0 | -0.4481 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
이뮤론 주식(IMRN)의 최신 뉴스
Orla Mining Ltd (ORLA) Performance and Fundamentals Dashboard tells a completely different story - setenews.com
Immuron stock tumbles after trial fails to meet primary endpoint By Investing.com - Investing.com UK
Immuron stock tumbles after trial fails to meet primary endpoint - Investing.com
Immuron Limited (IMRN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Immuron Limited announces quotation of new securities on ASX - MSN
Check Out IHS Holding Ltd (IHS)’s Trade Data Rather Than the Analysts’ Views - setenews.com
You might want to take a look at Embecta Corp (EMBC) now - setenews.com
Why UiPath Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Benzinga
ANWA Forecast — Price Target — Prediction for 2026 - TradingView
Immuron Limited (IMRN) Plunges Amidst Management Uncertainty and Bearish Market Sentiment - Markets Financial Content
Immuron New U.S. Department of Defense Award & Clinical Trial Update - GlobeNewswire Inc.
Immuron New U.S. Department of Defense Award & Clinical Trial Update - Sahm
[6-K] Immuron Ltd Current Report (Foreign Issuer) | IMRN SEC FilingForm 6-K - Stock Titan
Why Immuron Limited (ANW) stock gets analyst attentionJuly 2025 Recap & Safe Capital Growth Stock Tips - newser.com
IMRN Stock Price and Chart — NASDAQ:IMRN - TradingView
How Immuron Limited Depositary Receipt stock benefits from global expansion2025 Macro Impact & AI Driven Price Forecasts - Fundação Cultural do Pará
Does Immuron Limited (Common Stock) (ANWA) stock trade below intrinsic valueJuly 2025 Price Swings & Risk Controlled Daily Plans - Fundação Cultural do Pará
Immuron Reports Strong FY2025 Results and Outlines FY2026 Plans - TipRanks
[6-K] Immuron Ltd Current Report (Foreign Issuer) - Stock Titan
Immuron Limited Announces Quotation of New Securities on ASX - TipRanks
Holdings of Immuron Limited ADR (IMRN) are aligned with the stars - Setenews
Immuron Limited Receives FDA Approval for IMM-529 Investigational New Drug Application for Clostridioides difficile Infection Treatment - Quiver Quantitative
Immuron IMM-529 IND approved by FDA - GlobeNewswire
Immuron CEO to Present at AusBiotech Invest 2025 Conference - MSN
Immuron Announces Clinical Trial Update - Sahm
Immuron Ltd (IMC:ASX) - smallcaps.com.au
IMRN furnishes 6-K with ASX updates and Exhibit 99.1 - Stock Titan
Immuron Ltd. (ADR) (US45254U1016.SG) Stock Price, News, Quote & History - Yahoo
Immuron Q1 FY26 YoY growth - Finviz
Immuron Limited Announces 2025 Annual General Meeting - MSN
Immuron Submits IMM-529 IND to FDA - markets.businessinsider.com
Immuron (IMRN) Seeks FDA Green Light for Novel C. diff Treatment - GuruFocus
Immuron Limited Submits IND Application to FDA for IMM-529 to Combat Clostridioides difficile Infection - Quiver Quantitative
$400M Market Potential: Immuron's C. Difficile Drug IMM-529 Heads to FDA as Company Advances 3 Key Programs - Stock Titan
Immuron Limited Secures Auditor Consent for Financial Filings - MSN
What analysts say about Immuron Limited ANW stockBear Market Strategies & Low Risk Capital Gains - earlytimes.in
Is Immuron Limited Depositary Receipt forming a reversal patternJuly 2025 Earnings & Low Risk Entry Point Guides - newser.com
Is it too late to sell Immuron Limited Depositary ReceiptMarket Activity Report & Fast Moving Trade Plans - Newser
Does Immuron Limited Depositary Receipt fit your quant trading modelJuly 2025 Price Swings & High Win Rate Trade Tips - Newser
Statistical indicators supporting Immuron Limited Depositary Receipt’s strengthPortfolio Risk Summary & Real-Time Sentiment Analysis - Newser
What institutional flow reveals about Immuron Limited Depositary ReceiptEarnings Growth Summary & Entry Point Strategy Guides - Newser
Immuron Limited Depositary Receipt stock trend forecastWeekly Investment Summary & AI Optimized Trading Strategy Guides - Newser
Visualizing Immuron Limited Depositary Receipt stock with heatmapsAI Trading Forecast Based on Big Data - Newser
BNY Mellon Increases Stake in Immuron Limited - TipRanks
Immuron Limited Announces Cessation of Securities - TipRanks
What drives Immuron Limited Depositary Receipt stock priceHigh-yield capital appreciation - jammulinksnews.com
Immuron - GlobeNewswire Inc.
immuron ltd files for quotation of securities on ASX - Investing.com
IMRNImmuron Ltd Latest Stock News & Market Updates - Stock Titan
Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS) - BioSpace
Immuron: Targeted oral antibodies to treat infectious diseases - Innovation News Network
이뮤론 (IMRN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.36%
1.05%
자본화:
|
볼륨(24시간):